Additional equipment and capacity for drug product manufacturing in Wilmington, NC
AAIPharma Services/Cambridge Major Laboratories boost oral solid dosage manufacturing capabilities
AAIPharma Services Corp./Cambridge Major Laboratories, Inc. has announced additional capabilities and capacity for oral solid manufacturing in its Wilmington, NC facility. These investments have been driven by the significant growth in their drug product portfolio, particularly for orphan drugs and rare disease therapies.
Some of the recent additions to the ir oral solid capabilities include precision coating for our fluid bed dryer (GEA/MP-4), which allows for bottom spray coating for enteric release products. Also, it allows top spray granulatation and drying for materials from the (GEA/PMA-400) high shear mixer. The additional bottom spray coating capability was introduced along with the extruder spheronizer (GEA NICAS450/NICA140). Lastly, a Bosch KKE 1700 capsule checkweighter was added to increase the encapsulation capabilities. With the addition of this equipment and a second manufacturing shift, the solid dosage capacity has increased by approximately 35%.
"Our facility upgrades in Wilmington for Drug Product complement the overall progress of our laboratory and headquarters expansions. We are excited to have this top of the line equipment and added capability for specialized areas of drug product development and manufacturing," stated Ted Dolan, Chief Operating Officer.
These new capabilities complement our existing specialties which include Minitabs, Pediatric Sprinkles, Chewable Products, Sublingual Tablets, Orally Disintegrating Tablets, Extrusion Granules, and Extrusion Spheronization. AAI/CML also has the capability to manufacture potent drugs, controlled substances, and moisture/oxygen sensitive drugs. AAI/CML will continue to invest in unique capabilties and facility upgrades as its portfolio expands.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.